ホーム › 急性骨髄性白血病 › アラバマ州 › Birmingham
Birmingham、ALにおける急性骨髄性白血病の臨床試験
Birminghamとその周辺地域（約30マイル以内）の拠点で、急性骨髄性白血病に関する21件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
被験者募集中第2相
- University of Alabama at Birmingham Cancer Center, Birmingham
A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
被験者募集中第1相
- Children's Hospital of Alabama, Birmingham
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
被験者募集中第2相
- University of Alabama at Birmingham Cancer Center, Birmingham
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
被験者募集中第3相
- University of Alabama at Birmingham, Birmingham
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
被験者募集中第2相
- University of Alabama at Birmingham Cancer Center, Birmingham
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
被験者募集中第2相
- University of Alabama at Birmingham Cancer Center, Birmingham
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
被験者募集中第3相
- Children's Hospital of Alabama, Birmingham
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
被験者募集中第2相
- University of Alabama - Birmingham, Birmingham
Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
被験者募集中第3相
- Children's Hospital of Alabama, Birmingham
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
被験者募集中第1/2相
- O'Neal Comprehensive Cancer Center, University of Alabama, Birmingham
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
被験者募集中第1/2相
- Children's Hospital of Alabama, Birmingham
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
被験者募集中第2/3相
- University of Alabama Birmingham, Birmingham
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
被験者募集中観察研究
- University of Alabama at Birmingham, Birmingham
A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers
被験者募集中
- University of Alabama at Birmingham, Division of Hematology and Oncology, Birmingham
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
被験者募集中第2相
- University of Alabama Birmingham, Birmingham
Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies
被験者募集中第1相
- University of Alabama at Birmingham, Birmingham
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
被験者募集中第1相
- University of Alabama O'Neal Cancer Center, Birmingham
HPC Offered for PRESERVE Expansion
被験者募集中観察研究
- University of Alabama, Birmingham, Birmingham
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
被験者募集中第1/2相
- The Kirklin Clinic of UAB Hospital, Birmingham
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
被験者募集中健康なボランティア歓迎
- University of Alabama - Birmingham, Birmingham
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
被験者募集中第1相
- University of Alabama at Birmingham, Birmingham
他の都市における急性骨髄性白血病の試験
- Houston, TX85件の研究
- New York City, NY51件の研究
- Boston, MA44件の研究
- Seattle, WA41件の研究
- Baldwin Park, CA40件の研究
- Columbus, OH35件の研究
- Philadelphia, PA34件の研究
- Durham, NC33件の研究
- Atlanta, GA31件の研究
- Tampa, FL29件の研究
- Chicago, IL26件の研究
- Portland, OR25件の研究
Birminghamにおける他の研究
- がん（全種類）31件の研究
- 乳がん24件の研究
- 卵巣がん23件の研究
- 肥満症23件の研究
- 非小細胞肺癌22件の研究
- 多発性骨髄腫18件の研究
- COPD17件の研究
- 心血管疾患17件の研究
- 2型糖尿病16件の研究
- 子宮内膜がん16件の研究
- 過体重16件の研究
- 嚢胞性線維症16件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。